BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at one year in LUCENT-2, a Phase 3 maintenance study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderately-to-severely active ulcerative colitis (UC).

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.1

Everest Medicines Limited (HKEX 1952.HK, “Everest”, or the “Company”), announced today that the Ministry of Food and Drug Safety (MFDS) of South Korea accepted its New Drug Application (NDA) for Sacituzumab Govitecan.

MedMira Inc. announces a financial package of over $5.23 million to support the Company’s FY2022 corporate strategy by its largest shareholder and related parties.

JW Therapeutics presented the primary clinical response on Carteyva® in adults with relapsed/refractory follicular lymphoma in China at the 63rd American Society of Hematology Annual Meeting.

Genenta Science S.p.A. announced the pricing of its upsized initial public offering of 2.4 million American Depositary Shares, or ADSs, each representing one ordinary share, at a public offering price of $11.50 per share.

BeiGene, Ltd. announced that it has completed its previously announced initial public offering on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

Maravai LifeSciences Holdings, Inc., a global provider of life science reagents and services to researchers and biotech innovators, announced that the Company has been added to the Nasdaq Biotechnology Index effective prior to market open on Monday, December 20, 2021.

Analysis Indicates that Patients Requiring Blood Transfusions and Receiving Endari Required ~43% Fewer Units of Red Blood Cells.

AgeX Therapeutics , Inc. announced today a research collaboration with the University of California, Irvine (UCI).